Skip to main content
. 2002 Aug 12;99(17):11399–11404. doi: 10.1073/pnas.172398399

Fig 1.

Fig 1.

Inhibition of neuroblastoma tumors by anti-VEGF agents. Neuroblastoma xenografts were treated with the anti-VEGF agents (NX1838, n = 5; anti-VEGF antibody, n = 19; VEGF-Trap LD, n = 10; and VEGF-Trap HD, n = 10), with the results expressed as percent of control tumors (control NX1838, n = 5; control anti-VEGF antibody, n = 21; control VEGF-Trap LD, n = 10; and control VEGF-Trap HD, n = 10), with error bars representing SEM for treated tumors. Statistical analysis was done by Kruskal–Wallis analysis, with NX1838 (P = 0.08), anti-VEGF antibody (P = 0.12), VEGF-Trap LD (P = 0.10), and VEGF-Trap HD (P = 0.0009).